Figure 21 is titled “Change in PTSD symptoms for atypical antipsychotics compared with placebo.” The figure displays a forest plot reporting the standardized mean difference in CAPS and SIPS stratified by risperidone compared with placebo and olanzapine compared with placebo. The pooled meta analytic evidence from risperidone and olanzapine trials demonstrated efficacy of the class of atypical antipsychotics on CAPS and SIPS assessed PTSD symptoms (SMD, −0.48; 95% CI −0.81 to −0.16; I2 = 47.4%; p = 0.076)

Figure 21Change in PTSD symptoms for atypical antipsychotics compared with placebo

CAPS = Clinician-Administered PTSD Scale; CI = confidence interval; SMD = standardized mean difference; SIPS = Single Item PTSD Screener.

From: Results

Cover of Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder: A Systematic Review Update
Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder: A Systematic Review Update [Internet].
Comparative Effectiveness Review, No. 207.
Forman-Hoffman V, Middleton JC, Feltner C, et al.
Copyright Notice

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.